Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation

Autor:	Antonio Bisignani, Luigi Pannone, Vincenzo Miraglia, Juan Sieira, Saverio Iacopino, Gezim Bala, Erwin Ströker, Ingrid Overeinder, Alexandre Almorad, Anaïs Gauthey, Cinzia Monaco, Gaetano Paparella, Thiago Guimarães Osório, Antonio Sorgente, Luc Jordaens, Pedro Brugada, Gian‐Battista Chierchia, Carlo de Asmundis
Přispěvatelé:	Heartrhythmmanagement, Clinical sciences, Faculty of Medicine and Pharmacy, Cardio-vascular diseases, Medical Imaging, Cardiology
Rok vydání:	2022
Předmět:	Technology cryoballoon General Medicine Cryosurgery persistent atrial fibrillation Pulmonary vein isolation Treatment Outcome systematic review Pulmonary Veins Recurrence Atrial Fibrillation Left atrial posterior wall ablation Catheter Ablation Feasibility Studies Humans Prospective Studies Cardiology and Cardiovascular Medicine
Zdroj:	Pacing and Clinical Electrophysiology. 45:605-611
ISSN:	1540-8159 0147-8389
DOI:	10.1111/pace.14495
Popis:	Introduction: Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) to improve outcome in patients with persistent atrial fibrillation (AF). In this setting, LAPWI + PVI using cryoballoon ablation had comparable results with radiofrequency ablation (RFA). The aim of the study is to evaluate the feasibility and safety of a new cryoballoon ablation system in PVI + LAPWI isolation, comparing it with the historical platform. Methods: The study was a prospective, non-randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx™, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO™. Results: Acute isolation was achieved in all PVs in both groups and LAPWI was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between the two groups, except for lower temperatures during cryoapplications in the POLARx group, for both PVI and LAPWI. The complication rate was low and similar between groups. Conclusion: LAPWI+PVI with the novel POLARx™ Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO™ system.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f01a422ac62ed09a63387fa3407705a7 https://doi.org/10.1111/pace.14495 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.